Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.

Year-to-date money raised in public, private and other financings of biopharma companies.

Keymed Biosciences Co. Ltd. has raised HK$982 million (US$125 million) in a placement on the Hong Kong Stock Exchange (HKEX:2162) to commercialize its IL-4Rα monoclonal antibody CM-310 branded as Stapokibart, and to advance its larger pipeline.

BioWorld's offices were closed in observance of Juneteenth in the U.S. No issue was published Thursday, June 19.

A preview of the next edition of BioWorld, June 20, 2025

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bavarian, Naya, O2nix, Synfini.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioaegis, Diagonal, Medicovestor, Moleculin, Senti.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Aptevo, Camurus, F2G, Galderma, Oncoinvent, Scholar Rock, Shionogi.

Biopharmas raising money in public or private financings, including: Actio, Acurx, Biomea Fusion, Cantargia, Cynaptec, Lobe Sciences, Nanocell, Polyactiva.